BioIVT Acquires Fidelis Research in Fourth Acquisition of 2022

BioIVT Acquires Fidelis Research in Fourth Acquisition of 2022

BioIVT, a portfolio company of private equity firm Linden Capital Partners and formerly known as BioreclamationIVT, announced on September 26 its acquisition of Fidelis Research, a Sofia, Bulgaria-headquartered provider of biospecimen collection, laboratory processing and analysis, clinical research and patient support programs. Terms of the deal were not disclosed. With this acquisition, Westbury, New York-based BioIVT will be able to expand its support of precision medicine research in multiple therapeutic areas, most notably in oncology. Fidelis Research is an 85-site clinical biospecimen collection network in southeastern Europe. The company also has cell isolation capabilities and... Read More »
Pharos Capital Group Invests in Renal Care 360°

Pharos Capital Group Invests in Renal Care 360°

Pharos Capital Group, LLC, a middle-market private equity firm based in Dallas and Nashville, announced on September 12 a significant investment in Renal Care 360°, a nephrology practice and chronic care management company founded by renal care entrepreneur Joe Cashia. The size and terms of the transaction were not disclosed. This marks the fourth investment from Pharos’ latest flagship fund, Pharos Capital Partners IV, L.P. Pharos’ investment, along with additional equity investment from Renal Care 360°’s founding shareholders, will be used to support continued growth of the company’s RC360° Connected Care Program, geographic expansion through acquisitions and the... Read More »
Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics

Quidel Corporation Signs Definitive Agreement to Acquire Ortho Clinical Diagnostics

On December 23, Quidel Corporation and Ortho Clinical Diagnostics Holdings plc announced that they have entered into a definitive agreement in which Quidel will acquire Ortho, one of the world’s largest in vitro diagnostics companies. The transaction, which is subject to approval by both companies’ shareholders as well as customary closing conditions and regulatory approvals, is expected to close in the first half of 2022. Quidel will acquire Ortho for $24.68 per share of common stock, for a total consideration of approximately $6.0 billion, including $1.75 billion of cash, funded through cash on the balance sheet and incremental borrowings. The combined company will also acquire Ortho’s... Read More »
DispatchHealth Buys Dynamic Mobile Imaging

DispatchHealth Buys Dynamic Mobile Imaging

On December 14, DispatchHealth announced that it has acquired Dynamic Mobile Imaging (DMI), a 24-hour mobile x-ray and ultrasound company servicing all of Virginia, Maryland and the Washington D.C. area. The financial terms of the transaction were not disclosed. DispatchHealth provides on-demand acute care and an advanced level of medical care for people of all ages in the comfort of their own homes. The company works closely with payers, providers, health systems, EMS, employer groups and others to deliver care in the home to reduce unnecessary emergency room visits, hospital stays and readmissions. Originally launched as an in-home care urgent care startup, DispatchHealth sees mobile... Read More »
Akumin Buys Alliance Healthcare Services

Akumin Buys Alliance Healthcare Services

The diagnostic imaging provider Akumin Inc. (NASDAQ: AKU) has announced a definitive agreement to acquire Alliance Healthcare Services for approximately $820 million.  Alliance HealthCare Services provides outsourced advanced radiology and radiation therapy services across 45 states in the U.S. Alliance partners with more than 1,000 hospitals, health systems and physician practices. It was owned by Tahoe Investment Group.  Upon closing of the transaction, the combined company will offer the most comprehensive radiology and oncology solutions to patients in the U.S., operating in 46 states, with more than 1,000 hospital and health system customers, 154 independent outpatient radiology... Read More »
Danaher Corporation Buys Aldevron

Danaher Corporation Buys Aldevron

The medical device giant Danaher Corporation (NYSE: DHR) is back with a new acquisition valued at nearly $10 billion. The company is buying Aldevron for $9.6 billion from private equity firm EQT Partners. Founded in 1998, Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications. The business employs 600 people. No other financials for Aldevron were disclosed. The deal was financed by using cash on hand and/or proceeds from the issuance of commercial paper.  Aldevron will operate as a standalone operating company and brand within Danaher’s Life Sciences segment. The... Read More »